# 60 DEGREES PHARMACEUTICALS, INC. (SXTP) · Edgar & Edgarette company card

> 60 Degrees Pharmaceuticals (SXTP) grew revenue 65.5% in FY2025 to $1 million, operating margin -772% against a -3.8% median for pharmaceutical preparations, equity 64.5% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1946563 · fiscal year ended 2025-12-31 · 4 audited years read · [page](https://www.pops4.com/boards/company/SXTP) · [JSON](https://www.pops4.com/boards/company/SXTP.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $1M |
| Revenue growth, 1 year | 65.5% |
| Revenue growth per year | 65.1% |
| Operating margin | -771.6% (prior year -1599.0%) |
| Net margin | -732.8% |
| Operating cash flow | −$7M |
| Capital spending | $139,881 |
| Free cash flow | −$7M |
| Cash | $2M |
| Long-term debt | $152,775 |
| Total assets | $5M |
| Total equity | $3M |
| Equity ÷ assets | 64.5% |
| Return on equity | -212.8% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -33.25 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -771.6% in FY2025; revenue is hard to predict: its 80% range is ±57%
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $1.0M (FY2025), total debt $153K. Experience: revenue up 65.5% on the year, up 65.1% a year over 3 years; operating margin -771.6%, up from -1599.0%. Soundness: equity 64.5% of assets, return on equity -212.8%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $855K and $3.1M next year (method v4.1: its own 3-year record of growth weighed at 40% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $783K to $3.4M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -771.6% against a -3.8% median; growth 65.5% against 13.7%.

Range logged 2026-09-29, receipt d48238ea13939ecf, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 1, latest 2026-01-23 ([filing](https://www.sec.gov/Archives/edgar/data/1946563/000121390026007330/0001213900-26-007330-index.htm))
- Item 5.02 Director or officer change: 1, latest 2026-05-18 ([filing](https://www.sec.gov/Archives/edgar/data/1946563/000121390026058495/0001213900-26-058495-index.htm))

## Recent filings

- 8-K · filed 2026-10-27 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1946563/000121390026112698/0001213900-26-112698-index.htm)
- 8-K · filed 2026-10-23 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1946563/000121390026111864/0001213900-26-111864-index.htm)
- 8-K · filed 2026-10-06 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1946563/000121390026106979/0001213900-26-106979-index.htm)
- 8-K · filed 2026-09-14 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1946563/000121390026099702/0001213900-26-099702-index.htm)
- 8-K · filed 2026-09-08 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1946563/000121390026098056/0001213900-26-098056-index.htm)
- 10-Q · filed 2026-08-14 · [filing](https://www.sec.gov/Archives/edgar/data/1946563/000155485526001860/0001554855-26-001860-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001946563.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1946563

## Cite

POPS4, Edgar & Edgarette: 60 DEGREES PHARMACEUTICALS, INC. (SXTP) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/SXTP. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.